Modifying Blood Clots to Protect Small Heart Vessels in Heart Attack
Tests changing the clot before stenting, in adults having a severe heart attack.
Plain-language title generated from the registry record
Registry title: CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)
Key facts
- Where
- Odense, DenmarkSee the site
Where in Denmark
- Odense University HospitalOdense, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Odense University Hospital
- Trial code
- NCT07646977
- Record updated
- 2 September 2026
- Original description
The aim of this study is to evaluate the effects of coronary thrombus modification on preventing the microvascular damage associated with primary percutaneous coronary intervention (PCI), and to limit the associated myocardial damage assessed by myocardial salvage index after 3 months. Furthermore, the project will evaluate coronary microvascular damage assessed invasively using both continuous and bolus thermodilution before and after stent implantation. In addition, the project will evaluate the diagnostic ability and associations of pre-stenting invasive physiological measurement to cardiac magnetic resonance imaging measurements.Read full original descriptionShow less
CORonary Thrombus Modification to Prevent MIcrovascular Damage in Patients With ST-segment Elevation Myocardial Infarction (The CORMI Trial)
The aim of this study is to evaluate the effects of coronary thrombus modification on preventing the microvascular damage associated with primary percutaneous coronary intervention (PCI), and to limit the associated myocardial damage assessed by myocardial salvage index after 3 months. Furthermore, the project will evaluate coronary microvascular damage assessed invasively using both continuous and bolus thermodilution before and after stent implantation. In addition, the project will evaluate the diagnostic ability and associations of pre-stenting invasive physiological measurement to cardiac magnetic resonance imaging measurements.
Inclusion: ST-elevation at the J-junction in a minimum of two contiguous ECG leads with a minimum of ≥ 0.1 mV in all leads, except for V2 and V3 (which required ≥ 0.2 for men ≥ 40 years old, ≥ 0.25 in men < 40 years old, or ≥ 0.15 mV for all women) or new left bundle branch; Admission to hospital within 12 hours of symptom debut; Angiographic signs of a culprit lesion planned to be treated with primary percutaneous coronary intervention.
Exclusion: CMR contraindications (estimated glomerular filtration rate < 30 mL/min, magnetic or mechanically activated implants, or any prior metal implants, severe claustrophobia); Known asthma or severe chronic obstructive pulmonary disease; Expected inability to perform physiological measurements (due to severely tortuous arteries, ostial disease or very distal disease),; Age < 18 years or inability to provide informed consent; Life expectancy of < 12 months; Hemodynamically instability; Pregnancy or breastfeeding; Expected to or unavoidable to use thrombectomy.